GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ernexa Therapeutics Inc (NAS:ERNA) » Definitions » Long-Term Debt

ERNA (Ernexa Therapeutics) Long-Term Debt : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ernexa Therapeutics Long-Term Debt?

Ernexa Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.

Ernexa Therapeutics's quarterly Long-Term Debt increased from Jun. 2024 ($8.90 Mil) to Sep. 2024 ($32.04 Mil) but then declined from Sep. 2024 ($32.04 Mil) to Dec. 2024 ($0.00 Mil).

Ernexa Therapeutics's annual Long-Term Debt increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($6.77 Mil) but then declined from Dec. 2023 ($6.77 Mil) to Dec. 2024 ($0.00 Mil).


Ernexa Therapeutics Long-Term Debt Historical Data

The historical data trend for Ernexa Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ernexa Therapeutics Long-Term Debt Chart

Ernexa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
0.19 - - 6.77 -

Ernexa Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.77 8.01 8.90 32.04 -

Ernexa Therapeutics  (NAS:ERNA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Ernexa Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Ernexa Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Ernexa Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
Executives
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
Dorothy J Clarke director C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Brant Binder director C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft 10 percent owner 4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern 10 percent owner
Nicholas Jason Singer director 1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore director 10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson officer: Chief Financial Officer 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel officer: Interim President and CEO 10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman director TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright director 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536